A Phase 3 interventional study of Vorasidenib and Placebo in IDH-mutant High-grade Astrocytoma, sponsored by Institut de Recherches Internationales Servier. Not yet recruiting. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Institut de Recherches Internationales Servier · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to establish the efficacy and safety of vorasidenib in combination with TMZ, compared to placebo with TMZ, in participants ages 12 and older with newly diagnosed, isocitrate dehydrogenase (IDH) mutant high-grade astrocytoma. The study will include a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up, progression free survival follow-up, and survival follow-ups every 3 months until study completion. During Cycles 1 through 12 of the treatment period participants will receive TMZ along with either vorasidenib or placebo and then from Cycle 13 through the end of treatment participants will only receive vorasidenib or placebo. At study visits participants may undergo blood tests, magnetic resonance imaging (MRI), electrocardiogram (ECG), vital sign checks, questionnaires, and physical exams.
688 studies on the registry are indexed under Astrocytoma; 80 are open to participants now.
This study's planned enrollment of 550 is above the median of 31 across 531 interventional studies indexed under Astrocytoma.
Browse Astrocytoma studies →Institut de Recherches Internationales Servier is the lead sponsor of 68 studies on the registry; 5 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 9 (50%) have results posted.
Compared within Astrocytoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vorasidenib · Drug: Temozolomide (TMZ)
Drug: Placebo · Drug: Temozolomide (TMZ)
Tablets to be taken by mouth, once daily, until study participation stops
Tablets to be taken by mouth, once daily, until study participation stops
Tablets or capsules (depending on the form available in the participants country) to be taken by mouth, once daily on days 1-5 of each cycle, from Cycle 1 through Cycle 12. Cycles are 28-days each.
Progression-Free Survival (PFS)
The time from date of randomization to date of the first occurrence of progressive disease (PD) assessed by the Blinded Independent Review Committee (BIRC) per Response Assessment in Neuro-oncology (RANO) 2.0 or death from any cause, whichever occurs earlier.
Time frame: Through study completion, approximately 7.5 years
Overall Survival (OS)
The time from date of randomization to date of death due to any cause.
Time frame: Through study completion, approximately 7.5 years
PFS
As assessed by the investigator per RANO 2.0.
Time frame: Through study completion, approximately 7.5 years
Clinical Benefit Rate (CBR) as assessed by the investigator
Defined as a best overall response of complete response (CR), partial response (PR), or stable disease (SD)
Time frame: Through study completion, approximately 7.5 years
Clinical Benefit Rate (CBR) as assessed by the BIRC per RANO 2.0
Defined as a best overall response of complete response (CR), partial response (PR), or stable disease (SD)
Time frame: Through study completion, approximately 7.5 years
Objective Response Rate (ORR) as assessed by the investigator
Defined as a best overall response of CR or PR
Time frame: Through study completion, approximately 7.5 years
Objective Response Rate (ORR) as assessed by the BIRC per RANO 2.0
Defined as a best overall response of CR or PR
Time frame: Through study completion, approximately 7.5 years
Duration of Response (DOR)
Defined for participants with objective response (OR) as the time from the first documentation of OR to the first documentation of PD or death due to any cause, whichever occurs earlier.
Time frame: Through study completion, approximately 7.5 years
Time to Response as assessed by the investigator
Defined as the time from the date of randomization to the date of first documented CR or PR for responders
Time frame: Through study completion, approximately 7.5 years
Time to Response as assessed by the BIRC per RANO 2.0
Defined as the time from the date of randomization to the date of first documented CR or PR for responders
Time frame: Through study completion, approximately 7.5 years
Time to Next Intervention (TTNI)
Defined as the time from the date of randomization to the initiation of first subsequent anticancer therapy or death due to any cause, whichever occurs earlier.
Time frame: Through study completion, approximately 7.5 years
Progression-Free Survival 2 (PFS2)
Defined as the time from the date of randomization to first progression by investigator after initiation of subsequent anticancer therapy following initial progression as assessed by the BIRC or death due to any cause, whichever occurs earlier.
Time frame: Through study completion, approximately 7.5 years
Tumor Growth Rate (TGR)
As assessed by volume and defined as the percentage change in tumor volume every 6 months as assessed per BIRC.
Time frame: Through study completion, approximately 7.5 years
Number of adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs)
Time frame: Through study completion, approximately 7.5 years
Severity of AEs, SAEs, and AESIs
Time frame: Through study completion, approximately 7.5 years
Health-related quality of life (HRQoL) as assessed by the EQ-5D-5L questionnaire
The EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) scores range from 0 to 100 with a higher number indicating better health.
Time frame: Through end of treatment, up to 7.5 years
HRQoL as assessed by the EORTC QLQ C30 questionnaire
The European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ C30) QoL scores range from 0 to 100 with a higher number indicating better QoL.
Time frame: Through end of treatment, up to 7.5 years
Symptom burden as assessed by the MDASI-BT questionnaire
The MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) scores range from 0 to 10 with a higher number indicating more severe symptoms.
Time frame: Through end of treatment, up to 7.5 years
Symptom burden as assessed by the EORTC QLQ-BN20 questionnaire
The European Organization for Research and Treatment of Cancer quality of life brain tumor module (EORTC QLQ-BN20) scores range from 0 to 100 with a higher number indicating more severe symptoms.
Time frame: Through end of treatment, up to 7.5 years
No study locations are listed for this record.
Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.
Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Nov 2034, 92 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Recherches Internationales Servier